Baird Medical Devices Granted New Class III Certificate by China’s NMPA for Ceramic Thyroid Ablation Needle

Baird Medical Devices, Inc.

Baird Medical Devices, Inc. (“Baird Medical” or the “Company”), a leading microwave ablation (“MWA”) medical device developer and provider in China and the United States, today announced it has been granted a new Class III certificate by the National Medical Products Administration (NMPA) in China for its next generation Ceramic Thyroid Ablation Needle for the treatment of thyroid nodules on March 19, 2024.

Ceramic Thyroid Ablation Needle

The Ceramic Thyroid Ablation Needle utilizes rare earth ceramic materials that deliver exceptional heat resistance, chemical stability, and electrical insulation properties. These qualities empower the ablation needle with precise thermal control during surgeries, effectively minimizing postoperative complications and ensuring the safety and efficacy of procedures.

Unique Properties

The unique properties of ceramics facilitate a more uniform distribution of energy within the tissue during Microwave Ablation Treatments, mitigating the edge heating effects resulting from reflection and refraction. With an estimated 30% increase in mechanical strength derived from its robust material, the needle offers enhanced flexibility and reliability during tissue penetration, thereby improving operational accuracy and reducing the risk of breakage, particularly in delicate procedures.

The characteristics of rare earth ceramics optimize heating, resulting in more consistent microwave energy penetration, thorough energy release, and a notable 20-30% estimated increase in overall heating efficiency. Through the use of high-temperature sintering technology and a precision connection to the needle shaft via specialized processes, the ceramic needle’s efficiency is further enhanced.

“The introduction of the Ceramic Thyroid Ablation Needle signifies another breakthrough innovation in the field of microwave ablation and is a testament to our ongoing commitment to innovation and research,” said Ms. Haimei Wu, Founder and CEO of Baird Medical. “We eagerly anticipate the positive impact of this technology by enhancing the patient treatment experiences and saving lives in the years to come.”

Medical Device Classification Catalog

In 2023, China’s NMPA’s issued updates to the Medical Device Classification Catalog, and upgraded the Classification of Microwave Ablation Devices from a Class II to a Class III Certificate.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version